scholarly journals Hormone receptor and HER2 assessment in breast carcinoma metastatic to bone: A comparison between FNA cell blocks and decalcified core needle biopsies

2019 ◽  
Vol 128 (2) ◽  
pp. 133-145
Author(s):  
Jennifer Zeng ◽  
Salvatore Piscuoglio ◽  
Gitika Aggarwal ◽  
Joanna Magda ◽  
Maria A. Friedlander ◽  
...  
Keyword(s):  
Breast Carcinoma ◽  
Hormone Receptor ◽  
Core Needle

scholarly journals Interobserver Agreement Among Pathologists for Semiquantitative Hormone Receptor Scoring in Breast Carcinoma

2012 ◽  
Vol 138 (6) ◽  
pp. 796-802 ◽  
Author(s):  
David A. Cohen ◽  
David J. Dabbs ◽  
Kristine L. Cooper ◽  
Milon Amin ◽  
Terrell E. Jones ◽  
...  
Keyword(s):  
Breast Carcinoma ◽  
Hormone Receptor ◽  
Interobserver Agreement

scholarly journals Comparison of Immunocytochemistry and Immunohistochemistry on Breast Carcinoma: A Boon or a Bane?

2017 ◽  
Vol 9 (01) ◽  
pp. 005-010
Author(s):  
Kempula Geethamala ◽  
Venkataramappa Srinivasa Murthy ◽  
Bangalore Ramalingiah Vani ◽  
Madireddi Sudha Rao ◽  
Malugnalli Uddappa Thejaswini ◽  
...  
Keyword(s):  
Breast Carcinoma ◽  
Hormone Receptor ◽  
Growth Factor Receptor ◽  
Needle Aspiration ◽  
Hormone Receptor Status ◽  
Kappa Statistics ◽  
Diagnostic Reliability ◽  
Predictive Values ◽  
Receptor Status ◽  
Sensitivity Specificity

ABSTRACT Introduction: Breast carcinoma is the most common cancer among women in the urban Indian population. Conventionally, immunohistochemistry (IHC) is done to determine the hormone receptor status of the tumor. Immunocytochemistry (ICC) on fine‑needle aspiration cytology (FNAC) was carried out to determine the same hormone receptor status of the tumor. Objective: The study was undertaken to evaluate the diagnostic reliability of performing estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (Her2/neu) receptor status on FNAC by ICC and to compare the results with IHC. Materials and Methods: A 2 years 6 months prospective study conducted in the Department of Pathology, ESIC Medical College and PGIMSR and ESIC Model Hospital, Rajajinagar, Bengaluru, wherein 100 breast carcinoma patients’ samples both cytology and histology were collected. IHC and ICC were done by peroxidase antiperoxidase technique. Validations of the receptor status were analyzed using sensitivity, specificity, positive and negative predictive values (PPV and NPV), and kappa statistics for agreements between ICC and IHC. Results: ICC was positive for ER, PR, and Her2/neu in 53, 50, and 22 cases, respectively. For ER, a cytohistologic correlation of 98%, with a sensitivity of 96.3%, specificity of 100%, and PPV and NPV being 100% and 95.7%. For PR, concordance of 97%, with a sensitivity of 94.3%, specificity of 100%, and PPV and NPV being 100% and 94%. Her2/neu had an agreement of 89%, with a sensitivity of 72%, specificity of 95.5%, and PPV and NPV being 85.7% and 90.1%. Conclusion: ICC has been a boon and can be a paramount diagnostic adjunct to the routine investigations.

Expression of BCRP/ABCG2 Protein in Invasive Breast Cancer and Response to Neoadjuvant Chemotherapy

2021 ◽  
Author(s):  
Yan Shou Zhang ◽  
Chao Yang ◽  
Lei Han ◽  
Lei Liu ◽  
Yun Jiang Liu
Keyword(s):  
Breast Cancer ◽  
Breast Carcinoma ◽  
Neoadjuvant Chemotherapy ◽  
Tumor Size ◽  
Hormone Receptor ◽  
Molecular Subtypes ◽  
Therapy Response ◽  
Luminal A ◽  
Luminal B ◽  
Response To Neoadjuvant Chemotherapy

Background: Breast cancer resistance protein (BCRP), or ABCG2 (ATP-binding cassette sub-family G member 2), is an ATP-binding cassette (ABC) transporter that mediates energy-dependent transport of substrate drugs out of the cell. Its overexpression may contribute to intrinsic drug resistance in vitro. However, the current literature has not yet clarified the clinical significance of BCRP/ABCG2 in invasive breast carcinoma. Objectives: The purpose of this study was to validate the expression of BCRP/ABCG2 in invasive breast carcinoma and its role in response to neoadjuvant chemotherapy. Methods: In this study, a pretherapeutic core biopsy was performed in 222 patients. BCRP/ABCG2 expression in carcinoma tissue was measured by immunohistochemistry. BCRP/ABCG2 expression correlations with clinicopathological features, molecular subtypes, and therapy response after neoadjuvant chemotherapy were investigated. Results: The results showed that BCRP/ABCG2 was expressed in different molecular subtypes. The proportions of patients with high BCRP/ABCG2 expression were similar in luminal A and luminal B tumors (Luminal B, 80%; Luminal A, 78%), compared with other molecular subtypes (Triple-negative, 63%; HER-2+, 58%. P=0.05). BCRP/ABCG2 expression and the number of lymphatic metastases (𝑃=0.001) and tumor size (𝑃=0.011) demonstrated a statistically significant correlation. Low BCRP/ABCG2 expression was associated with an increased pathological complete response (pCR) rate of 38%, higher than the 19% in tumors with high BCRP/ABCG2 expression (P=0.002). In multivariable analysis, BCRP/ABCG2 and hormone receptor (HR) expression were identified as independent risk factors of pCR (P=0.003, P=0.013. respectively). Conclusions: BCRP/ABCG2 is highly expressed in hormone receptor-positive breast cancer. High BCRP/ABCG2 expression is associated with lymphatic metastasis, tumor size, and poor pCR. BCRP/ABCG2 may be a novel potential biomarker that can predict clinical progression and therapy response after neoadjuvant chemotherapy.

Agreement between core needle biopsy and surgical excision product: the importance of the invasive breast carcinoma grading system

2021 ◽  
Author(s):  
Rodrigo Justi Nogueira ◽  
Thales Müller Silvério Alves ◽  
Mário Jefferson Quirino Louzada ◽  
Deolino João Camilo-Júnior ◽  
José Cândido Caldeira Xavier-Júnior
Keyword(s):  
Breast Carcinoma ◽  
Core Needle Biopsy ◽  
Needle Biopsy ◽  
Surgical Excision ◽  
Invasive Breast Carcinoma ◽  
Grading System ◽  
Core Needle

scholarly journals Ultrasound-Guided Core Needle Biopsies of Breast Invasive Carcinoma: When One Core is Sufficient for Pathologic Diagnosis and Assessment of Hormone Receptor and HER2 Status

Diagnostics ◽  
2019 ◽  
Vol 9 (2) ◽  
pp. 54
Author(s):  
Hsin-Ni Li ◽  
Chuan-Han Chen
Keyword(s):  
Hormone Receptor ◽  
Invasive Carcinoma ◽  
Standard Procedure ◽  
Her2 Status ◽  
Breast Carcinomas ◽  
Single Institution ◽  
Core Needle ◽  
Pathologic Evaluation ◽  
Reliable Assessment ◽  
Invasive Carcinomas

Ultrasound (US)-guided core needle biopsy is considered the gold standard procedure with regard to preoperative diagnosis of breast carcinomas. However, there is no clear standard for the number of cores considered to be sufficient for pathologic evaluation, including the expression of surface hormone markers and HER2 status. Images and pathologic slides demonstrating breast invasive carcinoma from a single institution were thus retrospectively reviewed over a 12 month period. The results indicated that one core is sufficient for the diagnosis of invasive carcinomas, along with a reliable assessment of hormone receptor and HER2 status in many cases. The option of applying additional cores is recommended for some cases.

Sign in / Sign up

Export Citation Format

Share Document